7:00 a.m. | Registration and Continental Breakfast—Exhibits Open |
8:00 a.m. | Welcome and Opening Remarks, A. Osama Gaber, MD, FACS, Director, Methodist J.C. Walter Jr. Transplant Center, and Bernie Elliott, MD, Chief Medical Officer of Complex Medical Conditions and Provider Performance, Optum
|
8:15 a.m. | Improving Outcomes of Transplant for Lymphoma, George Carrum, MD, and Carlos A. Ramos, MD Patients with relapsed lymphoma may have a better outcome after transplant than with chemotherapy alone. This session will discuss current indications and outcomes after autologous transplant for lymphoma and how new cell therapies may be used to improve outcomes. Objectives: - Discuss current transplant regimens for lymphoma.
- Summarize outcomes for patients with lymphoma after an autologous transplant.
- Identify novel cell therapies that are used posttransplant for lymphoma.
|
9:00 a.m. | Novel Cell Therapies for Prevention and Treatment of Posttransplant Viral Diseases, Helen E. Heslop, MD Patients who undergo transplantation are on a regimen of medications to ensure their bodies do not reject the new organs or to prevent graft-versus-host disease. This session will illustrate the incidence of viral infections posttransplantation. The diagnosis, cell therapies and preventive treatment options for viral infection in stem cell transplantation will also be discussed. Objectives: - Recognize the incidence of viral infections posttransplant.
- Discuss the diagnosis, cell therapies and preventive treatment options for viral infections in stem cell transplantation.
|
9:45 a.m. | Break—Exhibits Open |
10:00 a.m. | Liver and Biliary Tumors: When Size Matters, R. Mark Ghobrial, MD, PhD Hepatocellular carcinoma (HCC) is a leading cause of death in the United States. Liver transplantation in patients with HCC that is within Milan criteria is associated with good clinical outcomes. However, there are many factors that contribute to outcomes for patients with HCC, and so transplant teams must utilize more liberal staging, such as University of California, San Francisco (UCSF) criteria for tumor staging in select populations of patients. This session will explore innovative practices for treatment of HCC by transplantation. Objectives: - Evaluate liver transplant outcomes for patients with HCC and the impact of UCSF criteria on long-term survival.
- List factors that may influence orthotopic liver transplant outcomes for patients with HCC.
- Compare and contrast the Milan criteria with the UCSF criteria for tumor staging in HCC.
- Explore new practices for treatment of HCC by transplantation.
|
10:45 a.m. | Transplant Hepatology in the Next Decade: The Changing Spectrum of Disease, Howard Monsour, MD There is a vast list of diagnoses that could ultimately lead to liver transplantation. The most common three causes for liver failure and for liver transplant referral are: NASH (nonalcoholic steatohepatitis), HCV (hepatitis C virus) and HCC. The risk factors for and complications of these diseases will be identified and discussed. This presentation will discuss the novel interventions and treatment strategies used to improve patient outcomes in liver disease, means of preventing liver failure, and special problems related to patients with these diagnoses after transplantation. Objectives: - Predict three leading causes for liver transplant referral in the next decade.
- Identify risk factors and the complications associated with NASH, HCV and HCC.
- Discuss effective treatment strategies to improve patient outcomes in liver disease.
|
11:30 a.m. | Lunch (provided)—Exhibits Open |
12:30 p.m. | Clinical and Ethical Considerations in Liver Transplantation, Joseph Galati, MD, and Courtenay R. Bruce, JD, MA In the evaluation of potential recipients for liver transplantation, patients’ history of alcohol abuse has been a long-standing debate amongst liver transplant team members. Standards held by physicians and payors appear to have validity but do not predict success. In this presentation, the moral and medical models of approaches to alcohol abuse will be compared and relevant ethical principles will be identified as they relate to transplantation. Objectives: - Review the current clinical approach to liver transplantation in patients with alcoholic liver disease.
- Discuss outcomes of liver transplantation for patients with a history of alcohol abuse.
- Distinguish moral from medical models of managing alcohol abuse.
- Identify relevant ethical principles as they relate to transplantation: beneficence, respect for autonomy and justice.
|
1:15 p.m. | Auto Islet Transplants and Cell Therapy for Diabetes, Omaima Sabek, PhD The pancreas is a glandular organ with endocrine functions, such as producing insulin, and exocrine functions that aid in the absorption of nutrients and in digestion. Two common maladies we see are chronic pancreatitis and diabetes. This session will address the clinical and physiological outcomes associated with total pancreatectomy for chronic pancreatitis and evaluate the current data on islet isolation and auto transplantation for chronic pancreatitis. Objectives: - Recognize clinical and physiological outcomes associated with total pancreatectomy for chronic pancreatitis.
- Examine the current data on islet isolation and auto transplantation in chronic pancreatitis.
- Evaluate the role of combined pancreatectomy and auto transplantation in patient rehabilitation.
- Describe current clinical and research therapies for diabetes.
- Contrast the outcomes of various surgical therapies to patient outcome measures.
- Outline future cell-based therapies for diabetic patients.
|
2:00 p.m. | Break—Exhibits Open |
2:15 p.m. | Heart Transplant and Autologous Stem Cell Transplants (ASCT) in Light Chain Amyloidosis, Rammurti T. Kamble, MD Initial manifestations of amyloidosis are variable and can often delay diagnosis or be missed entirely. The severity of cardiac involvement in amyloidosis largely affects patient survival. This presentation will describe the signs and symptoms associated with amyloidosis and how it is diagnosed. In addition, Dr. Kamble will discuss the role of ASCT for heart transplant patients with amyloidosis, along with the selection process used for ASCT. Objectives: - Describe the signs and symptoms that are associated with amyloidosis and how it is diagnosed.
- Discuss the role of ASCT for heart transplant patients with amyloidosis.
- Review the selection process used for ASCT and patients with amyloidosis.
|
3:00 p.m. | Management and Diagnoses of Infiltrative Cardiomyopathies in Transplantation, Arvind Bhimaraj, MD, MPH, FACC One of the most common infiltrative cardiomyopathies is cardiac amyloidosis. If the heart is infiltrated by amyloid protein, it can be part of either a systemic amyloidosis or a localized phenomenon. The etiology, pathogenesis and clinical progression of infiltrative cardiomyopathies will be described in this session. Dr. Bhimaraj will appraise the current therapies for heart failure and the role for multiorgan transplants, as well as discuss the current medications and results in infiltrative cardiomyopathies. Objectives: - Describe the etiology, pathogenesis and clinical progression of infiltrative cardiomyopathies.
- Appraise current therapies for heart failure and the role for multiorgan transplants.
- Discuss the current medications and results in infiltrative cardiomyopathies.
|
3:45 p.m. | Stem Cell Transplantation for Bone Disorders, Bradley K. Weiner, MD Nanotechnology and advances in stem cell research are opening the door for the use of stem cell transplantation in bone disorders. This session will describe the scientific basis for intervention in bone disorders and identify the specific disorders that can potentially be treated with stem cell transplantation. The exciting progress to date on stem cell-based therapy for bone disorders will be appraised. Objectives: - Describe the clinical and scientific basis for intervention in bone disorders.
- Identify the bone disorders that can be treated with stem cell transplantation.
- Appraise the progress to date on stem cell based therapy for bone diseases.
|
4:30 p.m. | Facility Tour: Methodist J.C. Walter Jr. Transplant Center & The Methodist Hospital Outpatient Center (optional) A 30-minute tour of the Transplant Center and Outpatient Center will be offered. Space is limited; registration is required. More information. |
5:00–6:30 p.m. | Complimentary Get-Acquainted Reception Please join us for complimentary drinks and hors d’oeuvres. This unique reception will provide attendees the opportunity to get further acquainted with our physicians and team at The Methodist Hospital. Musical performance by Houston Musician's Coalition! |